Korean Circ J.  2019 Dec;49(12):1201-1202. 10.4070/kcj.2019.3011.

Author's Reply to Potent P2Y₁₂ Receptor Inhibition in Korean Patients with Acute Myocardial Infarction

Affiliations
  • 1Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Korea. dryunkh@gmail.com

Abstract

No abstract available.


MeSH Terms

Humans
Myocardial Infarction*

Reference

1. Kim Y, Johnson TW, Jeong MH. Potent P2Y12 receptor inhibition in Korean patients with acute myocardial infarction. Korean Circ J. 2019; 49:1199–1200.
2. Yun KH, Cho JY, Rhee SJ, Oh SK. Temporal variability of platelet reactivity in patients treated with clopidogrel or ticagrelor. Korean Circ J. 2019; 49:1052–1061.
3. Park DW, Kwon O, Jang JS, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation. 2019; [Epub ahead of print].
4. Yun JE, Kim YJ, Park JJ, et al. Safety and effectiveness of contemporary P2Y12 inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study. J Am Heart Assoc. 2019; 8:e012078.
Full Text Links
  • KCJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr